Navigation Links
SectorWatch.biz Issues MarketStats on CVBT, BSX, MDT, CXM and DNA
Date:2/14/2008

IRVINE, Calif., Feb. 14 /PRNewswire/ -- SectorWatch.biz announces the availability of MarketStats on public equities that are in the news and driving markets today.

Investors can view all of SectorWatch.biz MarketStats free of charge by visiting: http://www.SectorWatch.biz -- Click on MarketStats

Today's MarketStats on Healthcare and Biotechnology companies include: CardioVascular Bio Therapeutics, Inc. (OTC Bulletin Board: CVBT), Boston Scientific Corp. (NYSE: BSX), Medtronic Inc. (NYSE: MDT), Cardium Therapeutics Inc. (Amex: CXM) and Genentech Inc. (NYSE: DNA).

To view a complete profile on CardioVascular Bio Therapeutics, Inc., visit our financial courier StockUpTicks.com (http://www.stockupticks.com).

Our MarketStats provide snapshots and analysis on public equities making news, driving industry sectors and affecting the markets. SectorWatch.biz is powered by Market Pathways, a leader in the representation of Small Cap equities for over twenty-five years. We are your discovery zone for under-followed stocks shaping the market.

Interested investors may subscribe for FREE to our StockUpTicks newsletter featuring a treasure trove of promising companies, daily market movers and free personal investment information -- visit http://stockupticks.com/register.html. D.R. Clark of Market Pathways is a member of the National Association of Securities Dealers, CRD # 4518163.

Contact us directly to have your company featured in StockUpTicks.com or SectorWatch.biz. For D.R. Clark's perspective on personal finance and the markets visit http://www.ClarkReport.com

Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SectorWatch.biz and StockUpTicks.com are properties of Market Pathways Financial Relations, Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies have not always approved the statements made in this report.

This report is neither a solicitation to buy nor an offer to sell securities but is for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor, analyst or licensed broker dealer and this report is not investment advice. MP has been granted twenty thousand restricted shares of CVBT common stock by CardioVascular BioTherapeutics Inc. for preparation and distribution of this report and other services over a ninety day period. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject company.


'/>"/>
SOURCE SectorWatch.biz
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
2. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
3. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
4. FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
5. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
6. CCPM Issues Statement on FDAs GIVE Initiative
7. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
8. CalbaTech Issues Update; Beginning Training for Adult Stem Cell Collections in Atlanta
9. HHS Issues First Department-Wide Report on Personalized Health Care
10. MichBio Issues 2007/8 Michigan Life Sciences Directory and Resources Guide
11. Pharmos Issues Letter to Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... Arizona (PRWEB) , ... October 09, 2017 , ... ... Kindred, a four-tiered line of medical marijuana products targeting the needs of consumers ... and packaging of Kindred takes place in Phoenix, Arizona. , As operators of ...
(Date:10/7/2017)... WA (PRWEB) , ... October ... ... industry leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution ... ProxiMeta Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C metagenome ...
Breaking Biology Technology:
(Date:8/23/2017)... 2017  The general public,s help is being enlisted in what,s thought ... in and on the human body –and are believed to affect health.  ... The Microbiome Immunity Project is the ... with the gut. The project's goal is to help advance scientific knowledge ... ...
(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
Breaking Biology News(10 mins):